Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

NUS researchers develop a way to automate the production of pharmaceutical small molecules

The discovery and development of new small-molecule compounds for therapeutic use involves a huge investment of time, effort and resources.

1 Jun 2021

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells.

20 May 2021

A new method for efficient and automated production of synthetic DNA

Chemically synthesized short DNA sequences are extremely important ingredients with countless uses in research laboratories, hospitals, and in industry, like in the method for identifying COVID-19.

12 May 2021

Brain-targeting drug delivery with nano-scaled apoptotic bodies

Scientists from Nanjing University and University of Macau have discovered nano-scaled apoptotic bodies (ABs) as a new brain-targeting drug carrier, bringing new promise for the Parkinson's Disease as well as other brain diseases.

7 May 2021

New efforts to improve the efficacy of nucleotide-based drugs against prostate cancer, bone metastasis

Published in the Advanced Functional Materials, University of Minnesota researcher Hongbo Pang led a cross-institutional study on improving the efficacy of nucleotide-based drugs against prostate cancer and bone metastasis.

21 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Single injection of RNA therapy improves vision in patient with genetic form of childhood blindness

A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.

1 Apr 2021

Scientists use specially designed gold nanoparticles to 'seek out' bone stem cells

Researchers at the University of Southampton have developed a new way of using nanomaterials to identify and enrich skeletal stem cells - a discovery which could eventually lead to new treatments for major bone fractures and the repair of lost or damaged bone.

29 Mar 2021

Quantum dot-based affinity biosensors in microfluidic systems offer an alternative SARS-CoV-2 diagnostics platform

In a new study published in Emergent Materials, researchers show how microfluidic systems integrated with quantum dot-based affinity biosensors can serve as a valuable platform to rapidly and accurately diagnose SARS-CoV-2 infection.

17 Mar 2021

The role of nanotechnology in the fight against COVID-19

Appearing in the journal Nanomedicine, the review summarized all the exciting advances made using diverse nanomaterials (polymeric, inorganic self-assembling materials and peptide-based) towards COVID-19 prevention, diagnosis and therapy.

15 Mar 2021

NTU scientists design new compound that could help reduce overactive immune response

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

10 Mar 2021

New evidence supports the use of antisense oligonucleotides as feasible therapeutic strategy for MDS

Many cognitive neurodevelopmental disorders are a result of too many or too few copies of certain genes or chromosomes.

5 Mar 2021

FDA approval provides targeted treatment option for patients with rare DMD mutation

Today, the U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Exons are pieces of DNA that provide information for making proteins in a person's genome).

25 Feb 2021

mRNA Therapeutics – Analytical and Bioanalytical Characterization

NewsMed interviews Anette Bak from AstraZeneca about her research on developments in mRNA therapeutics that she will present at Pittcon 2021.

From Pittcon 23 Feb 2021

Researchers develop ultra-small nanomedicines to target intractable cancers

Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.

19 Jan 2021

Replacing the RNA strand with DNA may enhance efficacy of ASO-based drugs

Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a heteroduplex oligonucleotide (HDO) model, have demonstrated augmentation of ASO-based drugs by replacing the RNA strand with DNA.

5 Jan 2021

A paper-based sensor for detecting COVID-19

News-Medical talks to Dipanjan Pan about the development of a paper-based electrochemical sensor that can detect COVID-19 in less than five minutes.

5 Jan 2021

Research shows how remdesivir inhibits SARS-CoV-2 replication

In a recent bioRxiv preprint, a research team from Germany, Goran Kokic et al. study the molecular mechanism of remdesivir-induced stalling of RdRp - using synthetic RNA chemistry, biochemistry, and cryo-electron microscopy.

2 Nov 2020

Research projects receive BTCA grants to develop novel drugs for various diseases

Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.

30 Oct 2020

Inhibition of SARS-CoV-2 with antisense oligonucleotides

A part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA is highly conserved. Researchers have used this as a target for designing antisense oligonucleotide gapmers to cleave the RNA and disrupt virus replication. Their research is published as a preprint on the online server bioRxiv in September 2020.

22 Sep 2020